Catalyst Wire Dossier Catalyst Wire Dossier

Entinostat (MS-275)

entinostat · Syndax Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Entinostat (MS-275), covering 2014-11-25 to 2025-03-20. Get the full timeline:

Most recent: Clinical Trial Update: Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) [Phase 1, Phase 2]

See pricing